More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$363882264
EPS
-0.87
P/E ratio
--
Price to sales
2.5
Dividend yield
--
Beta
1.130633
Previous close
$8.63
Today's open
$8.66
Day's range
$8.57 - $8.86
52 week range
$6.32 - $29.79
show more
CEO
Ron Kurtz
Employees
498
Headquarters
Aliso Viejo, CA
Exchange
NASDAQ Global Market
Shares outstanding
41116640
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Feb 18, 2026

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire • Feb 11, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PRNewsWire • Jan 22, 2026

RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Seeking Alpha • Jan 14, 2026

RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research • Jan 13, 2026

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.
GlobeNewsWire • Jan 11, 2026

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
GlobeNewsWire • Jan 2, 2026

RxSight, Inc. Announces Chief Financial Officer Transition
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.
GlobeNewsWire • Dec 22, 2025

RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City.
GlobeNewsWire • Nov 20, 2025

RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript
RxSight, Inc. ( RXST ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Oliver Moravcevic Ronald Kurtz - Co-President, CEO & Director Shelley Thunen - Co-President & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division David Saxon - Needham & Company, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Patrick Wood - Morgan Stanley, Research Division K. Gong - JPMorgan Chase & Co, Research Division Adam Maeder - Piper Sandler & Co., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, everyone.
Seeking Alpha • Nov 6, 2025

¹ Disclosures

Open an M1 investment account to buy and sell RxSight Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.